Preventing Heart Failure Readmission and Progression

Slides:

Advertisements

Similar presentations

Effect of Rapid Clinic Follow-Up After Hospital Discharge on 30- Day Heart Failure Readmission Lee Arcement, MD, MPH Dragana Lovre, MD.

Advertisements

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

PREVENTING READMISSIONS OF CONGESTIVE HEART FAILURE PATIENTS Daidreanna Whiteman Senior Project Columbus State University Summer 2014.

Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.

Quality of care, part 2: heart failure Kim A Eagle MD Albion Walter Hewlett Professor of Internal Medicine Chief, Clinical Cardiology Co-Director, Heart.

From Knowledge to Practice Translation A Multidisciplinary Intervention to Reduce 30 day Heart Failure Readmissions.

CHF Team Approach Peter Carson, MD Jacqueline Gannuscio, MSN, ACNP RN Washington DC.

PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.

Ridha Chakeer MD PGY3. Objectives: Approximately 5.2 million Americans are affected  accounts for more than 3 million outpatient visits to primary care.

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.

Home Health Remote Patient Monitoring For Heart Failure

Gregory M. Garrison, MD MS Society of Academic Primary Care 2016

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

Figure 1 Mechanisms of action of novel therapeutics for heart failure

CLINICAL DILEMMAS IN HEART FAILURE:

Emerging Concepts in Heart Failure

Acute Heart Failure.

Heart Failure and Hospital Readmissions

Heart Rate, HF Admissions, and Readmissions

Changing the IBD Paradigm

New Strategies to Prevent CV Events After Hospital Discharge

Cardiac Biomarkers.

Biomarkers in Heart Failure

PCP Perspectives Clinical Considerations in Hyperkalemia

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Individualizing Prophylaxis in Hemophilia

Treatment of Complicated Intra-abdominal Infections

Cost Effectiveness and Optimal Outcomes in HF

Adverse Neurohormonal Activation in HF Has Formed the Basis for Evidence-Based Pharmacologic Therapy

Heart Failure Management Coordinated Care Approaches

Heart Failure Prevention: Mission Impossible?

Treating HFrEF: Challenges Faced

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

Selected Causes of Cardiac Injury PEACE Trial High-Sensitivity Biomarker Substudy.

Medicare Hospital 30-Day Readmission Rates

Expert Insights on Complex Clinical Cases of Edema

The Heart Failure Team Heart Failure Care Map First 24 hours.

West Essex Frailty Pathway: Heart Failure

Remote Patient Management:

Evaluating New Therapies in HF

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

Using Heart Rate as a Biomarker in Clinical Practice.

When Is Biologic Therapy Appropriate for HS?

Case #1 Case #1 (cont) Case #1 (cont)

Learning Objectives CMS Measures in HF: 30-day Hospital Readmission Rates.

Revisiting the Pharmacoeconomics of HF

Improving 30-Day HF Readmission Rates With Biomarker-Guided Therapy

Challenging the Myths in Heart Failure With Reduced Ejection Fraction

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Embargoed until 10:45 a.m. CT/11:45 a.m. ET Sunday, Nov. 11, 2018

Heart Failure. Enhancing Myosin Activation and Cardiac Contractility: Implications for Heart Failure.

CAD and HF Often Coexist

New Strategies to Reduce HF Readmissions

Are We Making Progress in the Management of Huntington Disease?

Heart failure MANAGEMENT IN THE COMMUNITY

Improving Adherence to Antiplatelet Therapy After an ACS Event

Nat. Rev. Cardiol. doi: /nrcardio

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

HF-Related Hospitalization and Readmissions

AHF Epidemiology Readmissions Reduction Program.

Heart Failure Currently, an estimated 5.7 million Americans are living with heart failure. An additional 670,000 new cases are diagnosed annually, up.

Uptitration of Medications in HF: Start Low but Aim High and Stay High

In-Hospital Treatment for Heart Failure: New Approaches and a Renewed Sense of Hope?

Top Tips in Evidence-Based Care for HFrEF

Key Data on Improving Outcomes in HF Patients

QUALITY: COORDINATED CARE

Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Fresh perspectives ON BASAL Insulins in diabetes care

Presentation transcript:

Preventing Heart Failure Readmission and Progression

Topics to Discuss

CMS Measures in Heart Failure 30-Day Hospital Readmission Rates

Systems Appropriate to the Population

Outpatient Management If a Patient is Not Admitted, They Can Not Be Readmitted

Proportions of Readmissions for Causes Other Than the Condition at Initial Discharge

Predictor of Rehospitalization

Unmet Need – Progressive Disease

Evidence Based Therapies and Titration

Socioeconomic Impact

Team Approach to Disease Management

LCZ696: Sacubitril/valsartan Angiotensin Receptor Neprilysin Inhibitor (ARNi)

ARNi Mechanism of Action

Loop Diuretics Mechanism of Action

Ivabradine Mechanism of Action

Omecamtiv Mecarbil (OM) MOA Novel Selective Cardiac Myosin Activator

Serelaxin RELAX-AHF

There is a Need for Therapies That Will Prevent Damage and Progression

Summary – Progressive Disease Symptoms Are Only Part of the Story

Summary (cont) Progress But Continued Unmet Need

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)